Carcinoembryonic antigen-related cell adhesion molecule 5 (652-660)

Carcinoembryonic antigen-related cell adhesion molecule 5 (652-660) is a synthetic peptide fragment derived from the CEA-related cell adhesion molecule 5 (CEACAM5), a member of the immunoglobulin superfamily known for its role in cell adhesion, signaling, and intercellular communication. As a defined peptide sequence corresponding to amino acids 652 through 660 of CEACAM5, it offers a valuable tool for researchers investigating the molecular mechanisms underlying cell-cell interactions, tumor biology, and immune modulation. Its precise structural identity enables targeted studies of epitope mapping, protein-protein interactions, and the functional dissection of CEACAM5 domains relevant to cancer and immunological research.

Epitope mapping: The peptide corresponding to residues 652-660 of CEACAM5 serves as a critical reagent for epitope mapping studies. By providing a well-defined segment of the native protein, it enables researchers to identify and characterize the binding sites of monoclonal or polyclonal antibodies directed against CEACAM5. Such mapping is essential for the development and validation of antibody-based detection assays, as well as for understanding the specificity and cross-reactivity of immune recognition in cancer immunology and biomarker research.

Protein interaction analysis: As a representative motif within the CEACAM5 extracellular domain, the peptide is frequently utilized to investigate protein-protein interactions that govern cell adhesion and signaling. Researchers can employ this sequence in binding assays, surface plasmon resonance, or co-immunoprecipitation experiments to elucidate how CEACAM5 interfaces with other cellular receptors, ligands, or regulatory proteins. These studies provide mechanistic insights into the molecular determinants of cell adhesion, tissue architecture, and the disruption of such processes in oncogenic transformation.

Peptide-based assay development: The defined sequence of the 652-660 region supports the design of peptide-based assays for the quantitative or qualitative detection of specific antibodies, cellular responses, or enzymatic modifications. Incorporating this peptide into ELISA platforms, multiplex immunoassays, or peptide microarrays allows for the sensitive measurement of immune responses to CEACAM5-derived epitopes, which is particularly valuable in preclinical research settings focused on tumor immunology, vaccine evaluation, or immune monitoring.

Functional studies of cell adhesion: The 652-660 peptide fragment provides a model system for dissecting the functional contributions of specific CEACAM5 domains to cell adhesion processes. By utilizing the peptide in cell-based assays or as a competitive inhibitor in adhesion studies, researchers can assess the role of this sequence in mediating homophilic or heterophilic interactions, modulating signal transduction pathways, or influencing cellular migration. Such investigations advance the understanding of how CEACAM5 contributes to tissue organization and pathological changes in cancer progression.

Antigenicity and immunogenicity research: The peptide is also employed in studies aimed at evaluating the antigenic and immunogenic properties of CEACAM5-derived sequences. By presenting this defined epitope to immune cells or using it to stimulate antibody production in vitro, scientists can assess T-cell or B-cell recognition, analyze immune repertoire diversity, and identify candidate epitopes for further immunological investigation. These applications are instrumental in advancing knowledge of tumor-associated antigens and informing the design of immunological probes or research-grade reagents.

1. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

2. Myotropic activity of allatostatins in tenebrionid beetles

3. Cationic cell-penetrating peptides are potent furin inhibitors

4. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet

5. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics